Personalizing Cancer Treatments Empirically in the Laboratory: Patient-Specific Tumor Organoids for Optimizing Precision Medicine

  • Andrea Mazzocchi
  • Konstantinos Votanopoulos
  • Aleksander Skardal
Artificial Tissues (A Atala and JG Hunsberger, Section Editors)
  • 8 Downloads
Part of the following topical collections:
  1. Topical Collection on Artificial Tissues

Abstract

Purpose of Review

Cancer is often a complicated and dynamic disease, which makes determining the optimal treatment for a given patient a difficult endeavor. Moreover, even within a particular cancer type, different patients often have varying responses to the same therapies. Bioengineered tumor model systems specific to patients would allow preemptive screening of personalized therapies, facilitating identification of the most effective treatments prior to administration in the patients. Here, we provide an overview of organoid technology, and how these bioengineered tumor models can be harnessed for patient-centric personalized oncology.

Recent Findings

Organoid models have ranged from simple cell spheroids to more complex tumor-on-a-chip systems. The earliest of these models were comprised of easy to culture cell lines, but recent advances in 3D cell culture approaches have facilitated generation of human primary cell-based organoids. Importantly, recent efforts have been made to employ tumor biospecimens from human patients to create personalized tumor models for patient-specific predictive drug screening.

Summary

Bioengineering and tissue engineering technologies have advanced significantly in recent years, culminating in the capability to biofabricate tissue and tumor organoids derived from individual human patients. In the near future, we anticipate such models being implemented in parallel with clinical practice as patient-oriented screening tools, thereby improving the success rates of oncology.

Keywords

Precision medicine Personalized medicine Tumor organoids Biofabrication Tissue engineering 

Notes

Compliance with Ethical Standards

Conflict of Interest

Andrea Mazzocchi and Konstantinos Votanopoulos declare that they have no conflict of interest.

Aleksander Skardal reports a pending patent on cancer modeling platforms and methods of using the same.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Mills M, Estes MK. Physiologically relevant human tissue models for infectious diseases. Drug Discov Today. 2016;21(9):1540–52.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345(6194):1247125.CrossRefPubMedGoogle Scholar
  3. 3.
    Skardal A, Shupe T, Atala A. Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling. Drug Discov Today. 2016;21(9):1399–411.CrossRefPubMedGoogle Scholar
  4. 4.
    Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8(10):839–45.CrossRefPubMedGoogle Scholar
  5. 5.
    Esch MB, King TL, Shuler ML. The role of body-on-a-chip devices in drug and toxicity studies. Annu Rev Biomed Eng. 2011;13:55–72.CrossRefPubMedGoogle Scholar
  6. 6.
    Kang L, Chung BG, Langer R, Khademhosseini A. Microfluidics for drug discovery and development: from target selection to product lifecycle management. Drug Discov Today. 2008;13(1–2):1–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Astashkina A, Grainger DW. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments. Adv Drug Deliv Rev. 2014;69-70:1–18.CrossRefPubMedGoogle Scholar
  8. 8.
    • Zhang YS, Aleman J, Shin SR, Kilic T, Kim D, Mousavi Shaegh SA, et al. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. Proc Natl Acad Sci U S A. 2017;114(12):E2293–E302. This study describes organ-on-a-chip devices with a sophisticated biosensor suite that allows automated and real-time sensing of organoid health and behaviors CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    • Skardal A, Murphy SV, Devarasetty M, Mead I, Kang HW, Seol YJ, et al. Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform. Sci Rep. 2017;7(1):8837. This study demonstrates the development and implementation of multiple human organoids in a single perfused “body-on-a-chip” platform and showcases several integrated drug studies in which the function of one organoid type influences outcomes of the other organoid types CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Skardal A, Devarasetty M, Rodman C, Atala A, Soker S. Liver-tumor hybrid organoids for modeling tumor growth and drug response in vitro. Ann Biomed Eng. 2015;43(10):2361–73.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rosfjord E, Lucas J, Li G, Gerber HP. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem Pharmacol. 2014;91(2):135–43.CrossRefPubMedGoogle Scholar
  12. 12.
    Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer discovery. 2014;4(9):998–1013.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kamb A. What’s wrong with our cancer models? Nat Rev Drug Discov. 2005;4(2):161–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Williams SA, Anderson WC, Santaguida MT, Dylla SJ. Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab Investig. 2013;93(9):970–82.CrossRefPubMedGoogle Scholar
  15. 15.
    Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen. 2004;9(4):273–85.CrossRefPubMedGoogle Scholar
  16. 16.
    Ho WJ, Pham EA, Kim JW, Ng CW, Kim JH, Kamei DT, et al. Incorporation of multicellular spheroids into 3-D polymeric scaffolds provides an improved tumor model for screening anticancer drugs. Cancer Sci. 2010;101(12):2637–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Drewitz M, Helbling M, Fried N, Bieri M, Moritz W, Lichtenberg J, et al. Towards automated production and drug sensitivity testing using scaffold-free spherical tumor microtissues. Biotechnol J. 2011;6(12):1488–96.CrossRefPubMedGoogle Scholar
  18. 18.
    Skardal A, Devarasetty M, Rodman C, Atala A, Soker S. Liver-tumor hybrid organoids for modeling tumor growth and drug response in vitro. Ann Biomed Eng. 2015;43:2361–73.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Skardal A, Devarasetty M, Forsythe S, Atala A, Soker S. A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening. Biotechnol Bioeng. 2016;113:2020–32.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Devarasetty M, Wang E, Soker S, Skardal A. Mesenchymal stem cells support growth and organization of host-liver colorectal-tumor organoids and possibly resistance to chemotherapy. Biofabrication. 2017;9:021002.CrossRefPubMedGoogle Scholar
  21. 21.
    Benam KH, Dauth S, Hassell B, Herland A, Jain A, Jang KJ, et al. Engineered in vitro disease models. Annu Rev Pathol. 2015;10:195–262.CrossRefPubMedGoogle Scholar
  22. 22.
    Bhise NS, Ribas J, Manoharan V, Zhang YS, Polini A, Massa S, et al. Organ-on-a-chip platforms for studying drug delivery systems. J Control Release. 2014;190:82–93.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Polini A, Prodanov L, Bhise NS, Manoharan V, Dokmeci MR, Khademhosseini A. Organs-on-a-chip: a new tool for drug discovery. Expert Opin Drug Discovery. 2014;9(4):335–52.CrossRefGoogle Scholar
  24. 24.
    Barrila J, Radtke AL, Crabbe A, Sarker SF, Herbst-Kralovetz MM, Ott CM, et al. Organotypic 3D cell culture models: using the rotating wall vessel to study host-pathogen interactions. Nat Rev Microbiol. 2010;8(11):791–801.CrossRefPubMedGoogle Scholar
  25. 25.
    Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat Biotechnol. 2014;32(8):773–85.CrossRefPubMedGoogle Scholar
  26. 26.
    Skardal A. Bioprinting essentials of cell and protein viability. In: Atala A, Yoo JJ, editors. Essentials of 3D Biofabrication and Translation: Elsevier; 2015.Google Scholar
  27. 27.
    Skardal A, Atala A. Biomaterials for integration with 3-d bioprinting. Ann Biomed Eng. 2015;43(3):730–46.CrossRefPubMedGoogle Scholar
  28. 28.
    Skardal A, Devarasetty M, Soker S, Hall AR. In situ patterned micro 3D liver constructs for parallel toxicology testing in a fluidic device. Biofabrication. 2015;7(3):031001.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Murphy SV, Skardal A, Atala A. Evaluation of hydrogels for bio-printing applications. J Biomed Mater Res A. 2013;101(1):272–84.CrossRefPubMedGoogle Scholar
  30. 30.
    Jameson JL, Longo DL. Precision medicine--personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229–34.CrossRefPubMedGoogle Scholar
  31. 31.
    Wu SM, Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol. 2011;13(5):497–505.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Baker BM, Chen CS. Deconstructing the third dimension: how 3D culture microenvironments alter cellular cues. J Cell Sci. 2012;125(Pt 13):3015–24.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Huang L, Holtzinger A, Jagan I, BeGora M, Lohse I, Ngai N, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med. 2015;21(11):1364–71.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Sachs N, Clevers H. Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev. 2014;24:68–73.CrossRefPubMedGoogle Scholar
  35. 35.
    •• Mazzocchi AR, Rajan SAP, Votanopoulos KI, Hall AR, Skardal A. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening. Sci Rep. 2018;8(1):2886. This study describes biofabrication of tumor organoids and tumor-on-a-chip devices using actual patient tumor-derived biospecimens, and subsequent drug screening studies that correlate with patient drug responses. Google Scholar
  36. 36.
    Capulli AK, Tian K, Mehandru N, Bukhta A, Choudhury SF, Suchyta M, et al. Approaching the in vitro clinical trial: engineering organs on chips. Lab Chip. 2014;14(17):3181–6.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Fabre KM, Livingston C, Tagle DA. Organs-on-chips (microphysiological systems): tools to expedite efficacy and toxicity testing in human tissue. Exp Biol Med (Maywood). 2014;239(9):1073–7.CrossRefGoogle Scholar
  38. 38.
    Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med. 2014;20(6):616–23.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Strauss DG, Blinova K. Clinical trials in a dish. Trends Pharmacol Sci. 2017;38(1):4–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Carvajal-Vergara X, Sevilla A, D'Souza SL, Ang YS, Schaniel C, Lee DF, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature. 2010;465(7299):808–12.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Mou H, Brazauskas K, Rajagopal J. Personalized medicine for cystic fibrosis: establishing human model systems. Pediatr Pulmonol. 2015;50(Suppl 40):S14–23.CrossRefPubMedGoogle Scholar
  42. 42.
    Usta OB, McCarty WJ, Bale S, Hegde M, Jindal R, Bhushan A, et al. Microengineered cell and tissue systems for drug screening and toxicology applications: evolution of in-vitro liver technologies. Technology (Singap World Sci). 2015;3(1):1–26.Google Scholar
  43. 43.
    Mazzocchi AR, Soker S, Skardal A. Biofabrication technologies for developing in vitro tumor models. In: Soker S, Skardal a, editors. Tumor organoids. Berlin, Germany: Springer Nature; 2017.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Andrea Mazzocchi
    • 1
    • 2
  • Konstantinos Votanopoulos
    • 3
    • 4
  • Aleksander Skardal
    • 1
    • 2
    • 4
    • 5
  1. 1.Wake Forest School of Medicine, Medical CenterWake Forest Institute for Regenerative MedicineWinston-SalemUSA
  2. 2.Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences, Wake Forest School of MedicineWinston-SalemUSA
  3. 3.Department of SurgeryWake Forest Baptist HealthWinston-SalemUSA
  4. 4.Comprehensive Cancer Center at Wake Forest Baptist MedicalWinston-SalemUSA
  5. 5.Department of Cancer BiologyWake Forest School of MedicineWinston-SalemUSA

Personalised recommendations